3D human sebaceous glands technology for skin care applications

9 Jan 2018

New 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.

At NYSCC Cosmetic Congress, BASF Care Creations and the Cell Therapy Research Institute CTIBiotech presented the initial results of their joint research on 3D tissue models for the development and testing of bio-actives for skin care applications: After 2 years of research, the experts have now demonstrated both the ex vivo production of physiological sebum in a long-term culture of a 3D human sebaceous gland model, and the regulation of this sebum production by means of active ingredients.

3D human sebaceous glands technology for skin care applications

Using CTIBiotech’s 3D human sebaceous gland technology, scientists were able to improve BASF’s 3D skin model portfolio. The new 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.

“Working with BASF allowed us to validate a powerful technology for human skin care research in very little time,” said Dr. Nico Forraz, Chief Executive Officer at CTIBiotech. “This positions CTIBiotech as a world leader in innovative and even disruptive technologies for human cell-based bioassays, applied to dermo-cosmetics.”

“Compared to current in vitro methods, the 3D models developed by CTIBiotech allow analysis more in touch with human physiology and sebaceous gland metabolism,” said BASF’s project lead Dr Sabine Pain. “That’s how their technology helps us accelerate the development of innovative and highly reliable ingredients for the skin care market. Our understanding of sebaceous gland metabolism provides the basis for developing and testing advanced cosmetic bio-actives for skin care applications, and in particular skincare products for oily skin.”

“Because of their experience and expertise in developing solutions for the dermo-cosmetics market, BASF understands the benefits of collaborating with tissue engineering experts,” added Professor Colin McGuckin, Chief Scientific Officer and President of CTIBiotech. “The next evolution of the sebaceous gland model will be based on a 3D bio-printing technology that allows us to fully reproduce micro-glands into a full thickness skin model, in vitro.”

Read More

Related news

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more 
BioCity backs world's first Rx to OTC switch incubator

BioCity backs world's first Rx to OTC switch incubator

5 Sep 2019

Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.

Read more 
Dutch company receives €20 million for skin cancer diagnostic test

Dutch company receives €20 million for skin cancer diagnostic test

3 Sep 2019

The test can accurately predict the risk of having metastases present in the lymph nodes without having to undergo surgery to remove lymph nodes.

Read more 
AbbVie axes Rovalpituzumab Tesirine R&D program

AbbVie axes Rovalpituzumab Tesirine R&D program

2 Sep 2019

Independent Data Monitoring Committee recommended terminating the study due to lack of survival benefit.

Read more 
Improving anxiety-induced insomnia with lavender oil

Improving anxiety-induced insomnia with lavender oil

29 Aug 2019

New data shows pharmaceutical-quality lavender oil significantly improves anxiety-induced insomnia when taken as a daily capsule.

Read more 
Grant from Innovate UK to fund gel stabilisation technologies development

Grant from Innovate UK to fund gel stabilisation technologies development

28 Aug 2019

Atelerix Consortium awarded £267,000 Innovate UK Grant for collaboration with the Cell and Gene Therapy Catapult and Rexgenero on cell therapy stabilisation technologies.

Read more 
Exciting new vaccine targets killer disease TB

Exciting new vaccine targets killer disease TB

28 Aug 2019

Australian researchers produce early-stage vaccine which is inhaled into the lungs.

Read more 
Rapid adoption of Carterra’s LSA instrument drives European expansion

Rapid adoption of Carterra’s LSA instrument drives European expansion

20 Aug 2019

Company's antibody screening platform minimizes the risk of missing a blockbuster.

Read more 
IDT launches oPools Oligo Pools

IDT launches oPools Oligo Pools

19 Aug 2019

The longest, highest fidelity, and ready-to-use custom oligo pools on the market.

Read more 
FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more